Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by Annayyaon Sep 22, 2020 7:16pm
136 Views
Post# 31601538

RE:fall arrives, back to work

RE:fall arrives, back to work 30% SP increase with 1.9 million shares traded today and we closed at the highest point of the day. It's the highest activity and share price appreciation in over three months. This is really great news and proves that Promis Neurosciences is capable and determined to deliver the "three-pronged approach to combat AD: Detect with blood-based biomarkers, treat with PMN310 and prevent with a vaccine." Hopefully tomorrow the SP continues to increase to pass the 50 and 200 day SP moving average. Then if they could follow up with some great news on covid neutralizing antibodies, that would be amazing.
M101 wrote:


Well now we know the news that has been holding up the financing beyond Goldstein's usual comfort zone.  Welcome news indeed, but I sure hope there's more coming before he cuts the deal.  This should be political, this is the health care equivalent of climate change so we should be able to wangle a real grant, something far more substantial than 3rd party research cost reimbursement for covid19 evolution modeling.  Our consultants could actually earn their ridiculous pay package by getting us some real grants.  Or conversely, if they can't, wtf do we pay them for.   

 



Bullboard Posts